Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 60%Moderate 1 · 20%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d) with placebo · Depressive symptoms (HAM‐D) Scale from: 0 to 54 (worse)
  Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 70 participants
  Moderate
Direct match · question page
- Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d) with placebo · Response (≥ 50% reduction in HAM‐D score)
  Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  RR 1.7 [1.03, 2.78]
  1 study · 70 participants
  Low
Direct match · question page
- Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d) with placebo · Remission (HAM‐D total score ≤ 7)
  Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  RR 2.38 [1.09, 5.16]
  1 study · 70 participants
  Low
Direct match · question page
- Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d) with placebo · Quality of life ‐ not measured
  Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Direct match · question page
- Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d) with placebo · Dropouts
  Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  RR 1.02 [0.38, 2.72]
  1 study · 70 participants
  Low

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

Depressive symptoms · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Moderate

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

Leaving the study early · treatment‐resistant depression in adults

Augmentation of current antidepressant (fluoxetine 20 mg/d) with… showed no clear difference in dropouts compared with augmentation of current antidepressant (fluoxetine 20 mg/d) with… (low certainty).

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
RR 1.02 [0.38, 2.72]
1 study · 70 participants
Low

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

Proportions of participants responding to treatment ≥ 50% reduction in depression score from baseline to end of treatment. A larger RR indicates greater response to treatment in the SAMe group · treatment‐resistant depression in adults

Augmentation of current antidepressant (fluoxetine 20 mg/d) with… may leads to higher response (≥ 50% reduction in HAM‐D score) compared with augmentation of current antidepressant (fluoxetine 20 mg/d) with… (low certainty).

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
RR 1.7 [1.03, 2.78]
1 study · 70 participants
Low

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

Remission · treatment‐resistant depression in adults

Augmentation of current antidepressant (fluoxetine 20 mg/d) with… may leads to higher remission (HAM‐D total score ≤ 7) compared with augmentation of current antidepressant (fluoxetine 20 mg/d) with… (low certainty).

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
RR 2.38 [1.09, 5.16]
1 study · 70 participants
Low